Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

• Published in: Clinical infectious diseases 2024-06, Vol.78 (6), p.1473-1481
• Main Authors: Fowler, Vance G, Das, Anita F, Lipka-Diamond, Joy, Ambler, Jane E, Schuch, Raymond, Pomerantz, Roger, Cassino, Cara, Jáuregui-Peredo, Luis, Moran, Gregory J, Rupp, Mark E, Lachiewicz, Anne M, Kuti, Joseph L, Wise, Robert A, Kaye, Keith S, Zervos, Marcus J, Nichols, W Garrett
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Bacteremia - drug therapy; Bacteremia - microbiology; Drug Therapy, Combination; Endocarditis, Bacterial - drug therapy; Endocarditis, Bacterial - microbiology; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus - drug effects; Middle Aged; Standard of Care; Staphylococcal Infections - drug therapy; Staphylococcal Infections - microbiology; Staphylococcus aureus - drug effects; Treatment Outcome
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1093/cid/ciae043

Abstract Background Novel treatments are needed for Staphylococcus aureus bacteremia, particularly for methicillin-resistant S. aureus (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that is rapidly bactericidal and synergizes with antibiotics. Methods In Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT), a superiority-design phase 3 study, patients with S. aureus bacteremia/endocarditis were randomly assigned to receive a single dose of intravenous exebacase or placebo in addition to standard-of-care antibiotics. The primary efficacy outcome was clinical response at day 14 in the MRSA population. Results A total of 259 patients were randomized before the study was stopped for futility based on the recommendation of the unblinded Data Safety Monitoring Board. Clinical response rates at day 14 in the MRSA population (n = 97) were 50.0% (exebacase + antibiotics; 32/64) versus 60.6% (antibiotics alone; 20/33) (P = .392). Overall, rates of adverse events were similar across groups. No adverse events of hypersensitivity related to exebacase were reported. Conclusions Exebacase + antibiotics failed to improve clinical response at day 14 in patients with MRSA bacteremia/endocarditis. This result was unexpected based on phase 2 data that established proof-of-concept for exebacase + antibiotics in patients with MRSA bacteremia/endocarditis. In the antibiotics-alone group, the clinical response rate was higher than that seen in phase 2. Heterogeneity within the study population and a relatively small sample size in either the phase 2 or phase 3 studies may have increased the probability of imbalances in the multiple components of day 14 clinical outcome. This study provides lessons for future superiority studies in S. aureus bacteremia/endocarditis. Clinical Trials Registration.NCT04160468 Exebacase in addition to standard-of-care antibiotics was well-tolerated but failed to improve clinical response at day 14 in patients with Staphylococcus aureus bacteremia/endocarditis. This trial provides lessons for future superiority design studies in Staphylococcus aureus bacteremia/endocarditis.